2 May 2016

Plethora treatment wins NHS approval

Ben Jaglom

Specialist pharmaceutical concern Plethora Solutions Holdings (PLE) says it has won approval for its vaginal dryness treatment Hyalofemme from the NHS for prescription.

The agreement means that doctors in the UK will now be able to write prescriptions for Hyalofemme for the first time for atrophic vaginitis, commonly referred to as vaginal dryness. Traditional treatments involve the use of hormonal creams containing estrogen, but such creams are often inappropriate for cancer patients, who often suffer vaginal dryness as a side effect of cancer treatment.

Chairman Bill Robinson remarks the decision by the NHS should 'increase the commercial value of our pipeline by exploiting products secured last year'. He adds that the release of Hyalofemme is an 'important treatment' for atrophic vaginitis.

Following the announcement analysts at house broker Daniel Stewart held their forecasts of a year-end loss of £1.3 million (2010: loss of £1.5 million) on revenue up £100,000 to £1.2 million. They have pencilled in a loss per share of 2.5p for 2011 and a further loss of 3.4p a share for 2012.

Shares in Plethora were up 0.25p this morning following the announcement to 7.5p, the price at which Growth Company Investor recommended them earlier this month. A good sign for the company's prospects, Hyalofemme will be prescribed both for those being treated for cancer and women going through the menopause. We therefore reiterate our speculative buy rating.

Tags: AIM market, Menopause, Pharma, Plethora Solutions Holdings, Urology Company, Vaginal dryness

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Seeking Inspiration in neonatal care 

Inspiration Healthcare (AIM: IHC) has turned the usual development pattern for small medical technology companies on its head. Unlike typical small companies in the sector, it's already profitable with a cash generative distibution arm. It's aim now is to start pushing its own products through that pipeline.

GB going great guns

GB Group (AIM: GBG) has released a positive update on trading for the year to March. Operating profits are comfortably ahead of expectations and show 24 per cent growth. What’s slightly unsettling, especially given the demanding prospective p/e ratio of 30, is the news that long-time CEO Richard Law is to step down.

Looking after the talent

NetDimensions (AIM: NETD) shares enjoyed a strong recovery in the years following the financial crisis, only to run out of steam last summer. The subsequent 40 per cent fall in the share price looks like it’s now played out, with the stock responding well to recent results.

The Tide is rising

Crimson Tide (AIM: TIDE) is a tiny tech company with only £1.4 million sales just reported for the 2015 year. However it’s highly unusual for its size in that it’s profitable and generates cash. Sales are forecast to grow to £2.4 million next year and if this momentum can be built on, the shares could get interesting.

Mi-Pay moving the right way

Mi-Pay (AIM: MPAY) has announced results which show reduced losses and evidence that things are moving in the right direction. The company provides payment services for mobiles; so it’s certainly exposed to a growing markets. Costs and cash outflows have been reduced, while the value of customer transactions grew by 31 per cent in 2015.

Cropper beats expectations

Specialist paper maker James Cropper (AIM: CRPR) has pleased the market with an upbeat end-of-year trading statement. After a good run the shares had spent a few months consolidating; but today’s news has seen them move up 15 per cent and into new all-time high territory.

More News